Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Employment agrmnt
TCR2 THERAPEUTICS INC. (TCRR) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/12/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
06/01/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/01/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/01/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "FOURTH amended and restated CERTIFICATE OF INCORPORATION OF TCR 2 Therapeutics Inc.",
"SECOND Amended and Restated BY-LAWS OF TCR 2 THERAPEUTICS INC. ARTICLE I OFFICES SECTION 1.1. REGISTERED OFFICE. The registered office of the corporation shall be established and maintained at the office of The Corporation Trust Company, 1209 Orange Street, Corporation Trust Center, Wilmington, Delaware 19801, and said corporation shall be the registered agent of this corporation in charge thereof. SECTION 1.2. OTHER OFFICES. The corporation may have other offices, either within or without the State of Delaware, at such place or places as the board of directors of the corporation may from time to time appoint or the business of the corporation may require. ARTICLE II MEETING OF STOCKHOLDERS SECTION 2.1. PLACE OF MEETINGS. Meetings of the stockholders shall be held at such place, either wit..."
06/01/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
05/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/24/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Assignment of Lease by and between TCR2 Therapeutics Inc. and AstraZeneca Pharmaceuticals LP",
"Lease Modification Agreement by and between TCR2 Therapeutics Inc. and ARE-Maryland No. 31, LLC"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., May 11, 2023 - TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies’ complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the war on cancer,” said Garry Menzel, Ph.D., Presiden..."
05/05/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
04/20/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update • TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors • Following the expected Q2 2023 closing of the all-stock transaction, the combined company's cash runway is expected to extend into 2026 CAMBRIDGE, Mass., March 23, 2023- TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced fourth quarter and full-year 2022 financial results and provided a corporate update. “Focus and specialization are critical in the cell therapy space. The strategic combination with Ad..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/09/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/06/2023 8-K Amended existing or entered into new employment agreement with an officer
Docs: "Exhibit 2.1    EXECUTION VERSION   AGREEMENT AND PLAN OF MERGER   BY AND AmONG   Adaptimmune therapeutics plc,   cm Merger sub, Inc.   AND   tcr 2 therapeutics inc.",
"Agreement”) is made and entered into as of March 5, 2023 , by and among Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales, TCR 2 Therapeutics Inc. , a Delaware corporation and [STOCKHOLDER] . Each of Parent, the Company and the Stockholder are sometimes referred to as a “Party” and collectively as the “Parties",
"VOTING AND SUPPORT AGREEMENT   This Voting and Support Agreement is made and entered into as of March 5, 2023 , by and among  Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales,  TCR 2 Therapeutics Inc. , a Delaware corporation and  [SHAREHOLDER] . Each of Parent, the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Merger Agreement .   RECITALS   A.              Concurrently with the execution and delivery of this Agreement, Parent, the Company and CM Merger Sub, Inc...",
"FIRST AMENDMENT TO EMPLOYMENT AGREEMENT",
"Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Compelling clinical data with clear paths to products and multiple near-term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST",
"of Section 27 A of the Securities Act of 1933",
"significant operational advantages"
02/14/2023 SC 13G/A TANG CAPITAL PARTNERS LP reports a 7.1% stake in TCR2 Therapeutics Inc.
01/05/2023 8-K Quarterly results
01/03/2023 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy